Moving Beyond Symptom Subtypes: Testing a Common Dimension of Lifetime OCD Symptoms [0.03%]
超越症状亚型：检测一生中强迫症症状的共同维度
Abel Steven Mathew,Sarah L Garnaat,David R Strong et al.
Abel Steven Mathew et al.
Prescribing LAIs: From Completing the First Injection to Going Steady [0.03%]
从首次肌肉注射长效针到维持治疗：开具长效抗精神病药处方指南
Andrew Cutler,Meghan Grady,Alison Holladay
Andrew Cutler
Xavier Amador
Xavier Amador
Seetal Dodd,Stephen M Stahl,Michael Berk
Seetal Dodd
Shobha George,Anushree Sripathy,Aysha Rehman et al.
Shobha George et al.
VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia: A Narrative Review [0.03%]
治疗迟发性运动障碍的VMAT2抑制剂：综述文章
Amita R Patel,Robert Hauser,Leslie Citrome et al.
Amita R Patel et al.
Rebuilding the Atrophied Brain: Nasal Esketamine 6-month Therapy Expands Key Frontal and Hippocampal Regions and reduces neurofilaments serum levels in patients with major depressive disorder. The proof-of-concept of the depTesk (DEPression Treatment with [0.03%]
重建萎缩的脑：鼻用艾司氯胺酮六个月治疗可扩展重度抑郁症患者的关键额区和海马区并降低神经丝血清水平。depTesk（抑郁症治疗与艾司氯胺酮的研究）的概念验证。
Ana Rodriguez Lorente,Pilar Campos Navarro,Angela Gil Montoya et al.
Ana Rodriguez Lorente et al.
Susanna Rießland,Pia Baldinger-Melich,Nicoletta Margreiter-Neuwirth et al.
Susanna Rießland et al.
Efficacy of transcranial direct current stimulation combined with gait training in patients with Parkinson's Disease: Systematic review and meta-analysis [0.03%]
经颅直流电刺激联合步态训练改善帕金森病患者步行功能的系统评价和 Meta 分析
Ignacio Domínguez-Pera,David Lucena-Anton,Maria-José Estebanez-Perez et al.
Ignacio Domínguez-Pera et al.
Efficacy of Lumateperone in Depression Associated With Bipolar II Disorder: A Pooled Analysis of Late-Phase Clinical Trials [0.03%]
用于治疗Ⅱ型躁郁症相关抑郁的卢马曲班疗效：晚期临床试验汇总分析
Suresh Durgam,Hassan Lakkis,Susan G Kozauer et al.
Suresh Durgam et al.